苹果淫院

Updated: Sun, 10/06/2024 - 10:30

From Saturday, Oct. 5 through Monday, Oct. 7, the Downtown and Macdonald Campuses will be open only to 苹果淫院 students, employees and essential visitors. Many classes will be held online. Remote work required where possible. See Campus Public Safety website for details.


Du samedi 5 octobre au lundi 7 octobre, le campus du centre-ville et le campus Macdonald ne seront accessibles qu鈥檃ux 茅tudiants et aux membres du personnel de l鈥橴niversit茅 苹果淫院, ainsi qu鈥檃ux visiteurs essentiels. De nombreux cours auront lieu en ligne. Le personnel devra travailler 脿 distance, si possible. Voir le site Web de la Direction de la protection et de la pr茅vention pour plus de d茅tails.

Moshe Szyf

Academic title(s): 

Professor, Department of Pharmacology & Therapeutics

Moshe Szyf
Contact Information
Address: 

McIntyre Medical聽Sciences Building
3655 Prom. Sir-William-Osler
Room 1309/1310
Montreal, QC, H3G 1Y6

Email address: 
moshe.szyf [at] mcgill.ca
Phone: 
514-398-4400 ext. 00595
Department: 
Pharmacology and Therapeutics
Area(s): 
Epigenetics
Current research: 

Szyf received his Ph. D from the Hebrew University and did his postdoctoral fellowship in Genetics at Harvard Medical School, joined the department in 1989 and currently holds a James 苹果淫院 Professorship and GlaxoSmithKline-CIHR Chair in Pharmacology. He is the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at 苹果淫院 and is a Fellow of the Canadian Institute for Advanced Research Experience-based Brain and Biological Development program. 聽Szyf has been the founder of the first 鈥淧harma鈥 to develop epigenetic pharmacology 鈥淢ethylgene Inc.鈥 and the first journal in epigenetics 鈥淓pigenetics鈥.聽 Szyf lab has proposed two decades ago that DNA methylation is a prime therapeutic target in cancer and other diseases and has postulated and provided the first set of evidence that the 鈥渟ocial environment鈥 early in life can alter DNA methylation launching the emerging field of 鈥渟ocial epigenetics鈥.

Selected publications: 

Back to top